Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2005
11/03/2005WO2005102352A1 Pharmaceutical composition comprising a salt of mirtazapine
11/03/2005WO2005102351A1 Composition comprising a diuretic and/or cardiac glycoside for the treatment of dna viral infections of the eye
11/03/2005WO2005102350A1 Benzoxazine for treating respiratory tract diseases
11/03/2005WO2005102349A1 Pharmaceutical combinations containing benzoxazine for treating respiratory diseases
11/03/2005WO2005102348A1 Composition and method of decreasing renal ischemic damage
11/03/2005WO2005102347A1 Calcium sensitisers for treating symptoms of venomous bites and stings
11/03/2005WO2005102346A2 Use of c-kit inhibitors for treating fibrosis
11/03/2005WO2005102345A1 Use of rho kinase inhibitors in the treatment of hearing loss, tinnitus and improving body balance
11/03/2005WO2005102344A1 Pharmaceutical composition
11/03/2005WO2005102343A1 Use of flibanserin in the treatment of premenstrual and other female sexual disorders
11/03/2005WO2005102342A1 New pharmaceutical compositions for the treatment of sexual disorders ii
11/03/2005WO2005102341A2 Animal cover having a temperature altering device
11/03/2005WO2005102340A1 Piperazine melanocortin-specific compounds
11/03/2005WO2005102339A1 The use of cilostazol in preparing the medicine for bradycardia treatment
11/03/2005WO2005102338A1 Method of treating neuropathic pain using a crth2 receptor antagonist
11/03/2005WO2005102337A2 Use of a sphingoid base associated with nicotinic acid or a nicotinic acid amide in the form of a depigmentation agent
11/03/2005WO2005102336A1 Medicament
11/03/2005WO2005102335A2 Methods of treating sleep disorders
11/03/2005WO2005102334A2 Apparatus and method for transdermal delivery of fentany-based agents
11/03/2005WO2005102333A1 Methods of using and compositions comprising thalidomide for the treatment and management of pulmonary hypertension
11/03/2005WO2005102332A1 Therapeutic agent for arthrosis deformans
11/03/2005WO2005102331A1 Therapeutic agent for osteoporosis
11/03/2005WO2005102330A2 Amino methylated 2-pyridinones
11/03/2005WO2005102329A2 An innovative screening method for coronary heart disease and stroke
11/03/2005WO2005102328A1 Methods of treating hiv infection
11/03/2005WO2005102327A1 Dosage forms and methods of treatment using vegfr inhibitors
11/03/2005WO2005102326A2 Use of c-kit inhibitors for treating renal diseases
11/03/2005WO2005102325A1 Use of c-kit inhibitors for treating inflammatory muscle disorders including myositis and muscular dystrophy
11/03/2005WO2005102324A2 STABLE, NEUTRAL pH, VOC-FREE BIOCIDAL COMPOSITIONS OF 1,2-BENZISOTHIAZOLIN-3-ONE
11/03/2005WO2005102323A2 Process of preparing esters and ethers of probucol and derivatives thereof
11/03/2005WO2005102322A1 Use of a cgrp-antagonist combined with a serotonin-reuptake inhibitor in order to treat migraines
11/03/2005WO2005102321A1 Composition for acceleration of alcohol metabolism or recuperation from fatigue through gluconeogenesis
11/03/2005WO2005102320A1 Medicinal agent for treating viral infections
11/03/2005WO2005102319A2 Use of melatonin in preventing postoperative complications
11/03/2005WO2005102318A1 Use of c-kit inhibitors for treating hiv related diseases
11/03/2005WO2005102317A1 Methods of using and compositions comprising pde4 modulators for the treatment and management of pulmonary hypertension
11/03/2005WO2005102316A2 Use of coumarin derivatives
11/03/2005WO2005102315A1 Synthetic lactone formulations for pain control
11/03/2005WO2005102314A1 The use of butylphthalide homologues in preparing the drug of preventing and treating cerebral ischemic
11/03/2005WO2005102313A1 Preventive and/or therapeutic agent for chronic sinusitis
11/03/2005WO2005102312A1 Concentrated oxaliplatin solutions
11/03/2005WO2005102311A1 Agonists of a bitter taste receptor and uses thereof
11/03/2005WO2005102309A2 In vivo release of endogenous anti-microbial mediators by leukotriene b4 (ltb4) administration
11/03/2005WO2005102308A2 Crystalline and amorphous forms of efaproxiral sodium
11/03/2005WO2005102307A2 Beneficial effects of increasing local blood flow
11/03/2005WO2005102306A1 Anti-inflammatory analgesic adhesive patch
11/03/2005WO2005102305A2 Compositions of allosteric hemoglobin modifiers and methods of making the same
11/03/2005WO2005102304A1 Methods and compositions for the treatment of myocardial conditions
11/03/2005WO2005102303A2 Antiprostaglandins for the treatment of ocular pathologies
11/03/2005WO2005102302A1 Medicinal preparation
11/03/2005WO2005102301A2 Hydroxymethylbutyrate compositions and uses thereof
11/03/2005WO2005102300A1 α-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF RESTLESS LEGS SYNDROME AND ADDICTIVE DISORDERS
11/03/2005WO2005102299A1 Use of dopamine or the biological precursors thereof against algoneurodystrophy
11/03/2005WO2005102298A1 Medical substance mixtures containing resveratrol or resveratrol-derivatives, in addition to the use thereof in the production of medicaments
11/03/2005WO2005102297A2 Angiostatic agents for controlling choroidal neovascularisation after ocular surgery of trauma
11/03/2005WO2005102296A2 Combinations for the treatment of immunoproliferative skin disorders such as psoriasis
11/03/2005WO2005102295A1 Pharmanutrient composition(s) and system(s) for individualized, responsive dosing regimens
11/03/2005WO2005102294A2 Transdermal system secured against misuse
11/03/2005WO2005102291A1 Seamless capsule containing water-soluble active ingredient
11/03/2005WO2005102290A1 Pharmaceutical compositions of a biguanide and a sulfonylurea
11/03/2005WO2005102289A1 Clarithromycin extended release formulation
11/03/2005WO2005102288A2 Lozenge for delivery of dextromethorphan
11/03/2005WO2005102287A2 Pharmaceutical compositions for acute glucocorticoid therapy
11/03/2005WO2005102286A1 Method for the production of an abuse-proof, solid form of administration
11/03/2005WO2005102282A1 Transdermal delivery of beneficial substances effected by a hostile biophysical environment
11/03/2005WO2005102278A1 Method for preparation of poly-iclc and uses thereof
11/03/2005WO2005102276A1 Antimicrobial compositions
11/03/2005WO2005102275A2 Galantamine salts, method of producing it and nasal composition thereof
11/03/2005WO2005102274A2 Method of stabilizing disordered cefovecin sodium salt
11/03/2005WO2005102269A2 An amine drug-containing slow-release granule preparation based on particles with a coating layer and the corresponding method of production
11/03/2005WO2005102250A1 Composition comprising a monomer compound exhibiting an optical property, method making use of said composition, a monomer compound and a polymer containing said monomer compound and the use thereof
11/03/2005WO2005102247A2 Multi-phase contraceptive preparation based on a natural estrogen
11/03/2005WO2005102215A1 Methods of treatment with syk inhibitors
11/03/2005WO2005102049A1 Novel synthetic c-glycolipids, their synthesis and use to treat infections, cancer and autoimmune diseases
11/03/2005WO2005101982A2 A stable ophthalmic composition
11/03/2005WO2005089762A3 Pharmaceutical composition of (+)-erythro-mefloquine and its use in the treatment of an inflammatory condition
11/03/2005WO2005089742A8 Medicine for prevention or treatment of frequent urination or urinary incontinence
11/03/2005WO2005087208A3 Synergistic effect of compositions comprising carotenoids selected from lutein, beta-carotene and lycopene
11/03/2005WO2005086871A9 Compounds, compositions and methods for inhibiting or treating hiv-1
11/03/2005WO2005084692A3 Effect of beta-glucan on stem cell recruitment and tissue repair
11/03/2005WO2005084307A9 Use of lipid conjugates in the treatment of disease
11/03/2005WO2005082079A3 Tetracyclic lactam derivatives and uses thereof
11/03/2005WO2005079772A3 Combination of (s)-amlodipine and an ace inhibitor, and methods for reducing hypertension
11/03/2005WO2005079541A3 Terephthalamide peptidomimetic compounds and methods
11/03/2005WO2005072725A8 The use of l-butylphthalide in the manufacturing of medicines for the prevention and treatment of cerebral ischemia disease
11/03/2005WO2005070890A3 Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof
11/03/2005WO2005070464A3 A tablet formulation of clopidogrel bisulphate
11/03/2005WO2005070113A3 9n-substituted 6-11 bicyclic erythromycin derivatives
11/03/2005WO2005070077A3 Methods of using zonisamide as an adjunctive therapy for partial seizures
11/03/2005WO2005070006A3 Nitrosated and/or nitrosylated compounds, compositions and methods of use
11/03/2005WO2005067921A8 Pharmaceutical compositions comprising higher primary aliphatic alcohols and hmg coa reductase inhibitor and process of preparation thereof
11/03/2005WO2005067903A8 Pharmaceutical compositions comprising higher primary alcohols and ezetimibe and process of preparation thereof
11/03/2005WO2005067902A8 Novel compositions comprising higher primary alcohols and nicotinic acid and process of preparation thereof
11/03/2005WO2005067887A3 Formulations of ramipril
11/03/2005WO2005065655A3 Method for producing keto-l-gulonic acid spray granules
11/03/2005WO2005063777A8 Benzylphosphate and substituted benzylphosphate prodrugs for the treatment of pulmonary inflammation
11/03/2005WO2005062913B1 Triplide 5,6-derivatives as immunomodulators and anticancer agents
11/03/2005WO2005062761A3 Stabilized prednisolone sodium phosphate solutions
11/03/2005WO2005053607A3 Method for preventing hepatic encephalopathic episodes
11/03/2005WO2005049850A3 Compositions and methods for systemic nucleic acid sequence delivery
1 ... 4479 4480 4481 4482 4483 4484 4485 4486 4487 4488 4489 4490 4491 4492 4493 4494 4495 4496 4497 4498 4499 ... 7860